

Contents

Preface *xiii*

1	Targeted Protein Degradation – The Story So Far	1
	<i>Daniel H. O Donovan, Laura M. Luh and Philipp M. Cromm</i>	
1.1	Introduction to Targeted Protein Degradation (TPD)	1
1.1.1	What Can Be Expected from this Book?	2
1.2	Development of Targeted Protein Degradation: Chronology and Milestones	3
1.2.1	Milestone 1: Early Monovalent Protein Degradors – The Surprising Biology of Fulvestrant	4
1.2.2	Milestone 2: The First PROTACs – From Peptidic Degradors to Chemical Biology Tools	6
1.2.3	Milestone 3: Improving Drug-Like Properties – SNIPERs and Peptidomimetic VHL Binders	7
1.2.4	Milestone 4: PROTACs on the Rise – Small-Molecule Degraders Achieve <i>in vivo</i> PoC	8
1.2.5	Milestone 5: Sticking It to the Man! Molecular Glues	10
1.2.6	Milestone 6: Human After All – TPD in Clinical Trials	11
1.2.7	Milestone 7: Beyond the Proteasome – Inducing Proximity to Modulate Protein Levels	13
1.2.7.1	Is TPD Just the Beginning? Bifunctional Modulators of Post-transcriptional Modification	15
1.3	Conclusion and Outlook	17
	References	19
2	Cellular Principles of Targeted Protein Degradation	25
	<i>João Diamantino and Doris Hellerschmied</i>	
2.1	Basic Principles of Targeting Substrates to the Proteasome and Lysosomes	26
2.1.1	Ubiquitin-Proteasome System (UPS)	26
2.1.2	Lysosomal Targeting	27
2.2	Targeted Protein Degradation from the Cytosol and the Nucleus	29

2.2.1	Targeting to the Proteasome	29
2.2.1.1	Regulatory Target Recruitment	29
2.2.1.2	Target Engagement by the Ubiquitination Machinery	31
2.2.1.3	Engaging the Proteasome	32
2.2.2	Targeting to Lysosomes	33
2.3	Targeted Degradation from Membrane-Enclosed Organelles and the Extracellular Space	34
2.3.1	Degradation from the Plasma Membrane (PM) and the Extracellular Space	35
2.3.1.1	Internalization at the PM and Endosomal Sorting	35
2.3.1.2	Ubiquitination at the PM	37
2.3.2	Degradation from the Endoplasmic Reticulum (ER)	39
2.3.2.1	ER-Associated Protein Degradation (ERAD) – Proteasomal Degradation from the ER	39
2.3.2.2	ER Lysosome-Associated Degradation (ERLAD)	46
2.3.3	Degradation from the Golgi	47
2.4	Concluding Remarks	50
	References	50

3 E3 Ubiquitin Ligases as Molecular Machines and Platforms for Drug Development 63

Rafael M. Ioris, Katherine Ferris and Vincenzo D'Angiolella

3.1	Introduction	63
3.1.1	Ubiquitin Code and Targeted Protein Degradation	63
3.1.2	General Concepts of E3 Ligase Mechanism and Regulation	65
3.2	Substrate Recruitment and Degron Recognition	65
3.2.1	Regulating E3 Ligases Activity	66
3.3	RING E3 Ligases	67
3.3.1	Definition and Discovery	67
3.3.2	Subgroups	68
3.3.3	Insights into RINGs Regulation and Function	72
3.4	HECT E3 Ubiquitin Ligases	73
3.4.1	Definition and Discovery	73
3.4.2	Subgroups	73
3.4.3	Structure and Mechanism	74
3.4.4	Regulation	75
3.4.4.1	Intramolecular Interactions	75
3.4.4.2	Intermolecular Interactions	77
3.4.4.3	Post-translational Modifications	78
3.4.5	Insights into Hect Functions	79
3.4.5.1	Growth Signaling	79
3.4.5.2	Immunity	79
3.5	RING-IBR-RING (RBR)	85
3.5.1	Structure and Mechanism	85

3.5.2	Insights into Their Regulation and Function	85
3.6	Conclusion and Insights into Drug Development	86
	References	87
4	A Structural and Biophysical Perspective of Degradер Activity Through Ternary Complex Formation	107
	<i>Morgan S. Gadd and Marine C. Aublette</i>	
4.1	Introduction	107
4.1.1	Mechanism of Degraders Through Ternary Complexes	108
4.1.2	Ternary Complex Behavior	108
4.1.2.1	Binding Pose	108
4.1.2.2	Affinity and Cooperativity	108
4.1.2.3	Stoichiometry	110
4.1.2.4	Residency	110
4.1.2.5	Plasticity	110
4.1.2.6	Flexibility	111
4.1.3	Observing and Quantifying Ternary Complex Behavior	111
4.1.3.1	Biophysics	111
4.1.3.2	Structural Biology	112
4.2	X-ray Crystal Structures of Ternary Complexes	113
4.2.1	PROTAC-Induced Ternary Complex Structures	114
4.2.1.1	PROTACs Recruiting von Hippel–Lindau Protein (VHL)	114
4.2.1.2	PROTACs Recruiting Other E3 Ligases	123
4.2.1.3	Assessment of Structure-Guided Design of PROTAC Degraders	127
4.2.2	Molecular-Glue-Induced Ternary Complex Structures	128
4.2.2.1	Molecular Glues Recruiting Cereblon (CRBN)	129
4.2.2.2	Molecular Glues Recruiting Other E3 Ligases	136
4.3	Future Perspective on the Importance of Ternary Complexes in PROTAC Discovery and Development	139
4.3.1	Ternary Complexes – Is Seeing Believing?	139
4.3.2	Each (Ternary Complex) to Its Own	142
	References	143
5	Computational Modeling of PROTAC Ternary Complexes and Linker Design	151
	<i>Sven A. Miller, Grigori V. Andrianov, Victoria Mischley, Khadija A. Wharton, Jesse J. Chen and John Karanicolas</i>	
5.1	Introduction	151
5.2	PROTAC Ternary Complexes	153
5.3	Computational Modeling of PROTAC Ternary Complexes	156
5.4	PROTAC Design and Optimization	162
5.5	Emerging Methods for Computationally Designing and Optimizing PROTACs	164
5.6	Looking into the Future	168
	References	169

6 Molecular Glue Degraders: From Serendipity to Hunting and Design 177

Luis Nieto-Barrado, Ana Domostegui and Cristina Mayor-Ruiz

- 6.1 Introduction 177
- 6.2 “Molecular Glue” Concept 179
 - 6.2.1 Natural Compounds 179
 - 6.2.1.1 Molecular Glues 179
 - 6.2.1.2 Molecular Glue Degraders 182
 - 6.2.2 Synthetic Compounds 182
 - 6.2.2.1 Molecular Glues 182
 - 6.2.2.2 Molecular Glue Degraders 183
- 6.3 Synthetic Molecular Glue Degraders: Serendipitous Discoveries 184
 - 6.3.1 Molecular Glue Degraders Hijacking CRL4^{CRBN} (IMiDs): Broad Target Accommodation 184
 - 6.3.2 Molecular Glue Degraders Hijacking CRL4^{DCAF15} (Aryl Sulfonamides): High Shape Complementarity 186
 - 6.3.3 BCL6 Degraders: Induction of Polymerization 188
- 6.4 Synthetic Molecular Glue Degraders: Intentional Developments 188
 - 6.4.1 β -Catenin Molecular Glue Degraders 188
 - 6.4.2 Cyclin K Molecular Glue Degraders 189
 - 6.4.3 Prospective Discovery of IKZF1 Molecular Glue Degraders via “Up Assays” 192
 - 6.4.4 Structure-Guided Development of Helios (IKZF2) Molecular Glue Degraders 192
 - 6.4.5 Discovery of VHL-Binding Molecular Glue Degraders 193
- 6.5 Conclusions and Outlook 193
- References 195

7 Targeted Protein Degradation as a Therapeutic Strategy in Neurodegenerative Diseases 205

Fleur M. Ferguson

- 7.1 Introduction 205
- 7.2 Heterobifunctional Targeted Protein Degraders 206
 - 7.2.1 Misfolded Proteins 206
 - 7.2.1.1 Tau 206
 - 7.2.1.2 Alpha-Synuclein 208
 - 7.2.1.3 mHtt 209
 - 7.2.2 TDP-43 210
 - 7.2.3 Kinases and HDACs 210
- 7.3 Molecular Glues 211
- 7.4 Conclusion 211
- References 212

8	Insights and Future Perspectives of Covalent Protein Degraders	215
	<i>Xiaoyu Zhang</i>	
8.1	Introduction	215
8.2	Protein Degraders that Covalently Interact with the Substrate Proteins	217
8.2.1	HaloPROTAC	217
8.2.2	METAP2 and BTK	218
8.2.3	KRAS G12C	220
8.2.4	EGFR, ERK1/2, and ERR α	221
8.2.5	Monofunctional Protein Degraders	223
8.3	Protein Degraders that Covalently Interact with E3 Ubiquitin Ligases	224
8.3.1	RNF4	224
8.3.2	RNF114	225
8.3.3	KEAP1	226
8.3.4	FEM1B	227
8.3.5	SPSB2	227
8.3.6	DCAF16	229
8.3.7	DCAF11	231
8.4	Technologies for Covalent Protein Degradation Discovery	233
8.5	Outlook of Leveraging Covalent Chemistry for Targeted Protein Degradation	236
	References	237
9	Extending the Degradation Toolkit – mRNA Targeting as an Alternative Means to Affect Protein Levels	245
	<i>Andrei Ursu, Barbara Herdy and Hendrik Osadnik</i>	
9.1	Introduction	245
9.2	Life Cycle of Eukaryotic mRNAs	247
9.3	Splicing Shapes the Cell's Transcriptome	248
9.3.1	Aberrant Splicing Impacts the Transcriptome	249
9.3.2	Therapeutic Strategies to Change Protein Levels Through Splicing Regulation	251
9.3.2.1	Activating a Weak Splice Site in SMN2 to Increase Protein Production	252
9.3.2.2	mRNA Degradation of HTT by Inducing Aberrant Splicing in HD	252
9.3.2.3	Modulating the MKNK2 Isoform Balance with Splice Switching Oligonucleotides (SSOs)	253
9.3.2.4	Targeting Global AS with a Molecular “Glue” that Degrades RBM39	253
9.3.2.5	PROTAC-Mediated Degradation of Splicing Factor 3B1 (SF3B1)	254
9.3.3	Nuclear RNA Decay	255
9.3.3.1	Small-Molecule-Mediated Nuclear Decay of CUG Repeat Expansions	255
9.4	Cytoplasmatic RNA Quality Control Mechanisms	257
9.4.1	Incorrect Splicing Triggers NMD in the Cytoplasm	257

9.4.1.1	Harnessing Intronic Poly(A) Activation with ASOs	258
9.4.2	RNA Binding Proteins Recruit the mRNA Degradation Machinery	259
9.4.2.1	RNA-PROTAC-Mediated Degradation of LIN28A and RBFOX1	259
9.4.3	RNA Interference (RNAi) – microRNA, siRNA, and ASO Gapmers	260
9.4.3.1	Small-Molecule Enhancement of microRNA Processing	262
9.4.3.2	SMOL-Mediated Upregulation of miR-124 in Inflammatory Diseases	263
9.4.3.3	RIBOTAC-Mediated Degradation of Pre-miR-21 via Targeted Recruitment of RNase L	263
9.5	Conclusions	265
	References	266
10	The Future of Heterobifunctional Compounds: PROTACs and Beyond	273
	<i>George M. Burslem</i>	
10.1	Introduction	273
10.2	Protein Degradation Beyond Cancer	273
10.3	Emerging Heterobifunctional Modalities for Protein Degradation	275
10.3.1	PROTAC Variations	275
10.4	PROTAC-Inspired Technologies	277
10.5	Highjacking Autophagy	277
10.6	Degradation of Extracellular Proteins	279
10.7	Heterobifunctional Compounds Beyond Protein Degradation	281
10.8	Degradation of RNA	281
10.9	Modulating Phosphorylation	281
10.10	Targeted Acetylation	282
10.11	Potential Applications of Heterobifunctional Compounds to Modulate PTMS	283
10.12	Conclusions and Outlook	283
	References	283
11	Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery	289
	<i>Paola Martinelli, Christiane Kofink, Georg Boeck, Harald Weinstabl and Manfred Koegl</i>	
11.1	PROTACs in Drug Discovery: Why?	289
11.1.1	Targeting Proteins that Do Not Respond to Inhibition	289
11.1.2	Selective Inhibition of Isoforms	292
11.1.3	Increase in Potency Because of Catalytic Activity	293
11.1.4	Prolonged Duration of Effects	293
11.2	Routes of Application for PROTACs	294
11.3	Tackling DMPK Challenges of PROTACs	296
11.4	Molecular Glue Degraders: Definition, Advantages, and Challenges	300
11.4.1	Serendipitously Discovered Molecular Glue Degraders	301
11.4.1.1	Thalidomide Analogs	301
11.4.1.2	Aryl Sulfonamides	303

11.4.1.3	BCL6 Degradar BI-3802	303
11.4.2	PROTACs that Are also Molecular Glues: NX-2127 and KT-413	304
11.4.3	Rational Discovery of Molecular Glue Degraders	305
11.4.3.1	Screening-Based Discovery: CDK12 Inhibitors Degrade Cyclin K	305
11.4.3.2	Target-Based Discovery: Degraders of S37 Mutant β -Catenin	306
11.4.4	To Glue or Not to Glue for Targeted Protein Degradation	307
11.5	Targeted Protein Degradation: Here to Stay	307
	References	308
12	Taming the Beast: How to Optimize DMPK–PD Properties of Oral Degraders	313
	<i>Caroline Rynn, Arthur Van De Vyver, Antje Walz, Carina Cantrill and Matthias Wittwer</i>	
12.1	Physicochemical and ADME Properties of Degraders	314
12.1.1	Physicochemical Properties	314
12.1.2	Permeability	315
12.1.3	Transporters	317
12.1.4	Solubility	318
12.1.5	Plasma Protein Binding	318
12.1.6	Drug–Drug Interactions	319
12.1.7	Clearance	319
12.1.8	Oral Absorption	320
12.2	Degraders: PK/PD challenges and the Role of Modeling and Simulation	323
12.2.1	Pharmacological Processes of Degraders and PK/PD Aspects	323
12.2.2	PK/PD Considerations During Drug Discovery and Development	324
12.2.3	Translational PK/PD and Human Dose Prediction for Targeted Protein Degraders	330
12.3	Gaps and Future Perspectives	330
	References	331
13	PROTAC[®] Protein Degraders: Bridging the Divide from Chemical Biology Tools to Clinical Candidates	337
	<i>Erika M.V. Araujo and Keith R. Hornberger</i>	
13.1	Introduction	337
13.2	Physicochemical Properties	339
13.3	Pharmacokinetics	341
13.4	<i>in vitro</i> ADME Assays	342
13.5	Pharmacodynamics	342
13.6	Toxicology	347
13.7	Clinical Case Studies	349
13.8	Conclusion	355
	References	356
	Index	361